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Drug resistanceition of the major role played by antimicrobial peptides (AMPs) in sustaining an
effective host response to immune challenges was greatly inﬂuenced by studies of amphibian peptides. AMPs
are also widely regarded as a potential source of future antibiotics owing to a remarkable set of advantageous
properties ranging from molecular simplicity to low-resistance swift-kill of a broad range of microbial cells.
However, the peptide formula per se, represents less than ideal drug candidates, namely because of poor
bioavailability issues, potential immunogenicity, optional toxicity and high production costs. To address these
issues, synthetic peptides have been designed, reproducing the critical peptide biophysical characteristic in
unnatural sequence-speciﬁc oligomers. Thus, the use of peptidomimetics to overcome the limitations
inherent to peptides physical characteristics is becoming an important and promising approach for
improving the therapeutic potential of AMPs. Here, we review most recent advances in the design strategies
and the biophysical properties of the main classes of mimics to natural AMPs, emphasizing the importance of
structure–activity relationship studies in ﬁne-tuning of their physicochemical attributes for improved
antimicrobial properties.
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The discovery of the ubiquitous occurrence of antimicrobial
peptides (AMP) and their role as major host defense effectors was
greatly motivated by the emergence and spread of resistance to
antibiotics, while their potential use in ﬁghting resistance has been
stimulating AMPs research for over two decades. A most peculiar
ﬁnding is the realization that AMPs are present in multiple isoforms
with a common set of properties enabling their grouping as families.
While the signiﬁcance of this ﬁnding raised intriguing questions, some
of which unanswered to date, these isoforms have certainly helped in
identifying the importance of charge and hydrophobicity as the most
crucial elements responsible for antimicrobial properties. Thus, AMPs
made in the skin of Hylidae and Ranidae frogs and belonging to the
dermaseptin family, display a remarkable duality, presenting both
common yet distinct structural and functional attributes which
moreover are rather typical to the vast majority of AMPs of any origin.
Therefore, while their study as families has revealed most fascinating
ﬁndings of both practical and evolution signiﬁcances (see P. Nicolas, in
this issue, for an authoritative review), their structure activity
relationships (SAR) studies have helped revealing new strategies for
speciﬁc targeting ofmicroorganisms and shed new light on the roles of
various parameters such as amphipathy, supramolecular organization
and conformational ﬂexibility, on the interaction with microbial
targets, as detailed below.
1.1. Antimicrobial peptides and antimicrobial resistance
It is now widely recognized that the AMP concept could play a
promising role in ﬁghting the presently raging microbial resistance to
conventional antibiotics [1,2]. Historically, resistance to antimicrobial
agents actually predates the introduction of the ﬁrst antibiotic
(Penicillin) into clinical usage [3]. Because the ﬁrst antibiotics,
excluding the synthetic sulfa drugs, were all identiﬁed or derived
from natural products, resistance determinants had already accumu-
lated in the environments from which these agents originated. It was
only a short period of time before selection pressures allowed these
environmental resistance determinants to become incorporated into
the pathogenic bacteria that were being treated with the new
antibiotics [3]. In addition, medical and agricultural practices of the
past 50 years have promoted resistance development and spread in
both human and animal pathogens, compromising effective
chemotherapy of infectious diseases [4]. Today, many important
pathogens are resistant to multiple antimicrobial classes, covering
most, sometimes all, clinically useable antimicrobials. Infections
caused by these so-called multidrug resistant (MDR) organisms are
costly to treat while the treatment is increasingly prone to failure
[5,6].
Bacterial resistance to antimicrobials comes in many ﬂavors,
relying typically on drug inactivation [7] or target site modiﬁcation/
mutation [8]. Reduced drug accumulation owing to limited uptake or
enhanced efﬂux is also an important resistance mechanism for certain
classes of antimicrobials [9]. Another mechanism is that of phenotypic
resistance owing to speciﬁc growth modes (e.g., bioﬁlms) during
infection. It is prevalent amongst bacterial pathogens and likely plays
a major role in in-vivo resistance and treatment failure despite
indications of in-vitro drug susceptibility [10]. Overall, the clinical
impact of resistance is immense, characterized by increased cost,
length of hospital stay and mortality.
Thus, it was time to consider new classes of antibiotics such as the
AMPs [11] whose mode of action promises both low susceptibility to
MDR mechanisms and high activity against a vast range of
microorganisms [12]. AMPs are produced by most species of life,
from prokaryotes [13,14] to plants [15,16], insects [17–20], amphibians
[21–25] and mammals including humans [26–28], as part of the
organism's host defense mechanism. As major effectors of the innateimmune system, AMPs complement the highly speciﬁc but relatively
slow adaptive immune system [29,30]. Unlike the acquired immune
mechanisms, endogenous AMPs, which are constitutively expressed
or induced, provide fast and effective means of defense. Most of these
gene encoded peptides are mobilized shortly after microbial infection
and act rapidly to neutralize a broad range of microbes [31].
1.2. Modes of action
Many AMPs are deﬁned as membrane-active molecules. While
their lytic activity is generally not mediated by a chiral center [32], the
exact mechanism behind this activity is not fully understood.
Nevertheless, based on the available data, all proposed modes of
action have implicated the cationic and hydrophobic nature of the
AMP in its initial interaction with the negatively charged lipids in
bacterial membranes [33,34] while some variations are expected in
non-bacterial targets. Presumably, the amphipathic structural
arrangement of AMPs plays an important role in this mechanism.
Due to their cationic nature AMPs are electrostatically attracted to
negatively charged microbial surfaces such as lipopolysaccharide
(LPS) in Gram-negative bacteria [35] and teichoic and teichuronic
acids in Gram-positive bacteria [36]. Binding of AMPs to these most
external elements is generally not directly implicated as solely
responsible for bacterial death. On contrary, this binding afﬁnity
maybe required for preferential accumulation of AMPs in bacteria.
Binding is eventually used as a “jumping-board” to insinuate into
inner layers reaching for the cytoplasmic membrane as elegantly
illustrated in the self-promoted uptake hypothesis [33].
Once the cytoplasmic membrane is reached, AMPs interact with
negatively charged groups of the external leaﬂet. At this stage, linear
AMPs re-organize and assume an optimal amphipathic conformation
where the hydrophilic face interacts with the phospholipid head
groups whereas their hydrophobic face is inserted in the bilayer core.
Note, a similar interaction with peptide mimics is depicted in Fig. 6.
Such interactions can lead to a wide variety of structural distortions/
damages to the membrane architecture and can result from various
possible mechanisms: 1) peptidemolecules accumulate parallel to the
surface and affect themembrane in a detergent-likemanner, a process
known as a carpet-like mechanism [35]. 2) self association of peptide
molecules to form pores [37–39]; 3) in the “toroidal-pore model”
insertion of peptides into the membrane is envisioned to induce lipids
to bend contiguously around peptide aggregates until a water core is
formed, lined by both the inserted peptide and the lipid headgroups
[40]. Solution NMR studies have played an important role in providing
atomistic-level structures of AMPs. Along with solid-state NMR these
studies have provided high-resolution data for different types of
mechanisms by AMPs such as barrel-stave pores by pardaxin [41],
carpet/toroidal typemechanism by LL37 [42] andMSI peptides [43]. A
recent study of the toroidal-pore model, conducted with the magainin
analog MG-H2 and a model phospholipid bilayer, showed that the
pore is stabilized by a diffuse distribution of peptides which bind to
the rim of the pore, adopting a largely parallel orientation to the
membrane plane, rather than the previously described perpendicular
orientation [44].
Lipid composition alone might account for the preferential activity
against bacteria. Whereas microbial membranes are enriched in
anionic lipids, mammalian cell membranes usually contain fewer
anionic lipids which moreover are mostly found in the inner leaﬂet
[36,45,46]. The presence of sterols in the target membrane also can
account for selectivity. Cholesterol can reduce AMPs potency due to its
stabilization effect on the lipid bilayer or to its interaction with the
AMP [2,47,48]. Differences in transmembrane potential (Δψ), electro-
chemical gradient determined by extents and rates of proton ﬂux
across themembrane, were also implicated in selectivity of AMPs [46].
In practice however, highly hydrophobic AMPs are capable of
interacting with both microbial and mammalian membranes [49]
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[50–53]. This fact points to the relatively higher importance of the
hydrophobic forces at play, compared with those of charge.
AMPs interactions with membranes are thus known to lead to a
variety of damages ranging from anions segregation and cell surface
topology alterations [54,55] to cancellation of the membrane-barrier
function via its depolarization and permeation, eventually. In some
cases however, “harmless” interactions of AMPs with the plasma
membranewere proposed to affect cell viability following internaliza-
tion and interaction with intracellular targets [2,56]. Translocation to
the cytoplasm enables AMPs to target a variety of additional molecules
such as DNA [57], RNA and enzymes [58,59] or inhibit their synthesis
[60–64]. For example, buforin II binds to DNA and RNA and alters their
electrophoretic mobilities in agarose gels [57]. A hybrid AMP, designed
from the ﬂounder pleurocidin and the frog dermaseptin, was shown to
inhibit E. coli nucleic acid and protein synthesis at the lowest inhibitory
concentration, without damaging the cytoplasmic membrane [63].
1.3. Antimicrobial peptides as drug candidates
Owing partly to the above described properties, it is now well
recognized, that the AMP speciﬁc sequence by itself is not crucial in
deﬁning antimicrobial activity, which rather depends upon physico-
chemical attributes including charge, hydrophobicity and structure
[36]. Consequently, although non-speciﬁc modes of action might
indeed decrease pathogens abilities to develop resistancemechanisms
to AMPs [65,66], common characteristics between microbial and
mammalian cell-membranes seem to be responsible for relatively low
selectivity of AMPs (certainly compared with conventional antibio-
tics). As drug candidates, AMPs present various additional disadvan-
tages including reduced activity in presence of salts and divalent
cations [67–70], susceptibility to pH changes [70,71] and to proteases
and other plasma components [72]. AMPs can also suffer from poor
pharmacokinetic issues and high production costs [46,73–75]. Thus,
although the use of peptides composed of D-amino acids only is
sometimes contemplated owing to their high resistance to proteolysis
[76,77] this option often signiﬁcantly increases the product costswhile
there is no published pharmacokinetic evidence for enhanced
bioavailability of D-peptides.
There is thus, a clear need for alternative strategies to overcome
AMPs drawbacks, particularly as potential systemic therapeutic
agents. A wide range of SAR studies aiming at better understanding
the mechanisms of action of natural AMPs, have considerablyFig. 1. Chemical formula of representative AMP-mimics. Upper structures (from left to right)
Arylamide, phenylene ethynylene and acyl-lysyl oligomers (brackets deﬁne the building bloenhanced our appreciation of the main factors inﬂuencing their
actions, leading in recent years, to increasing attempts to derive this
kind of information from systematic variations of model peptide
sequences using several approaches: combinatorial libraries [78–80],
minimalistic approach [81,82] and sequence templates [36,83,84] or
from design of non-natural peptide mimics. The rational being that
reproduction of critical peptide biophysical characteristics in an
unnatural, sequence-speciﬁc oligomer, should presumably be
sufﬁcient to endow antibacterial efﬁcacy, while circumventing the
limitations associated with peptide pharmaceuticals [85–87].
2. Peptidomimetics
The termpeptidomimetic is used here in a broad sense, referring to
essentially any oligomeric sequence designed to mimic a peptide
structure and/or function but whose backbone is not solely based on
α-amino acids (representative chemical structures are shown in Fig.
1). Peptidomimetics can thus be based on polymers that mimic a
peptide primary structure through the use of amide bond isosteres
and/or modiﬁcation of the native peptide backbone, including chain
extension or heteroatom incorporation. Typical classes of anti-
microbial peptidomimetics will be brieﬂy outlined (for recent reviews
see references [88,89]), then we shall focus on oligomers of acylated
lysines. Other interesting “mimic” systems such as ceragenins [90] and
diastereoisomers [91] will not be included.
2.1. Peptoids
Poly-N-substituted glycines (peptoids) differ from peptides only in
that peptoid side chains are attached to the backbone amide nitrogen
rather than to the α-carbon [92], which among other attributes,
renders them protease-resistant [93]. The poly-N-substituted glycine
structure of peptoids prevents both backbone chirality and intrachain
hydrogen bonding; nevertheless, peptoids can be driven to form
helical secondary structures via a periodic incorporation of bulky, α-
chiral side chains [94,95]. Incorporation of homochiral side chains can
give rise to polyproline type-I-like helices with a periodicity of
approximately three monomers per turn [96,97]. The threefold
periodicity of the peptoid helix facilitates the design of facially
amphipathic structures similar to those formed by many AMPs; for
example, the trimer repeat (X–Y–Z)n forms a peptoid helix with three
faces, composed of X, Y, and Z residues. in vitro activities of certain
antimicrobial peptoids are similar to those of many AMPs, they exhibit: An α-peptide sequence and its β-peptide and peptoid counterparts. Lower structures:
cks).
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toxicity, for example SAR studies on peptoids revealed a twelve
residue compound termed 1-pro6 which had potent antibacterial
activity (MIC values of 3.1 and 1.6 μM against E. coli and B. subtilis) and
low hemolytic activity (LC50 of N110 μM against hRBC) [98].
2.2. β-Peptides
DeGrado et al. ﬁrst reported de novo design of antibacterial β-
peptides, short polymers of β-amino acids [99]. This class of
polyamides folds into turns, helices, and sheet-like structures,
analogous to the secondary structures found in proteins composed of
α-amino acids but display higher resistance to enzymatic degradation.
These compounds were highly active against E. coli but also against
erythrocytes. For example the longest peptide, which consisted of 18
β-amino acids, induce 50% hemolysis (LC50) at 80 nM which is
considerably greater than that of melittin (0.5 μM) [99]. Extension of
this work resulted in analogs with signiﬁcantly reduced hemolytic
activity [100]. The authors recognized that the lack of selectivity of
their original β-peptides arose from excessive hydrophobicity.
Other studies demonstrated that “β2/β3” type peptides, which are
composed of a mixture of β2 (β-amino acid were the side chain is on
the α-carbon) and β3 (β-amino acid were the side chain is on the β-
carbon) amino acids, can display selectivity [101,102]. For example the
“mixed” β2/β3-nonapeptide 1 (composed of 9 amino acids) showed
MIC range of 6–100 μM against a panel of bacteria with an LC50 of
175 μM against hRBC. The pharmacokinetic proﬁle of an α/β peptide
termed “β3/α tetrapeptide 2” indicating stability in-vivo after i.v. and
p.o. administrations (1 and 2 mg/kg, respectively) displayed similar
rates of clearance in the blood (about 90% per hour) [103].
Studies comparing activities against a panel of bacteria of two
helix-forming compounds, β-17 and a synthetic magainin derivative,
revealed comparable antibacterial activities (e.g., MIC of 6.2μMagainst
E. coli) but β-17 was less hemolytic [104]. Further studies of β-
peptides with ﬂexible acyclic residues incorporation revealed that
variation in helical propensity did not signiﬁcantly affect antibiotic
activity [105]. A recent work on oligomers containing a 1:1 pattern of
α- and β-amino acids showed that having a globally amphiphilic
helical conformation is not a requirement for selective antibacterial
activity [106,107]. In contrast to β-peptides, whose activity was clearly
correlated with amphiphilic helical conformations [105] studies with
α/β sequences revealed that scrambled versions can manifested
stronger antibacterial activity than the globally amphiphilic most
favorable helical conformations, suggesting that stable folds do not
necessarily determine antibacterial potency. Interestingly, the trend in
hemolytic activities among these compounds was quite different from
the trend in antibacterial activity [106] suggesting that stable folds
might determine hemolytic potency.
2.3. Arylamide oligomers
Tew et al. later reported a class of facially amphiphilic arylamide
oligomers that utilized hydrogen bonding to produce conformationally
stiff backbones [108]. Arylamide oligomers which were designed with
the aid ofmolecular dynamics simulations, exhibited a broad spectrum
antibacterial activity [108] with a mechanism of action resembling
native antimicrobial peptides. For example a typical oligomer
(composed of two subunits) displayed a MIC of 25 μM against E. coli
and induced calcein release from phosphatidylserine/phosphatidyl-
choline bilayers, suggesting membranolytic mode of action. Modiﬁca-
tions to the initial oligomers using various hydrophobic and
hydrophilic side chains or by switching benzene with pyrimidine,
have yielded several potent and moderately selective compounds
[108–110]. For example compound 10 (with a single pyrimidine in the
backbone) showed ∼10 fold improvement in antibacterial activity
(MIC of ∼1 μM) compared to the benzene ring analog (compound 11)which has a MIC of ∼18 μM. Both compounds displayed LC50 against
hRBC at ∼20 μM [109]. Thus, unlike β-peptides, these studies seem to
suggest that rigidifying the conformation of arylamide oligomers could
lead to improved antibacterial activity and selectivity.
2.4. Phenylene ethynylenes
Tew et al. reported selective antibacterial activity of phenylene
ethynylene oligomers, with a strictly hydrocarbon backbone [111,112].
The most active compound, composed of three phenyl rings
(compound 1), showed potent antimicrobial activity against a large
panel of pathogenic bacteriawith aMIC range of 0.4–14 μMand LC50 of
153 μM against hRBC. Compound 1 also did not induce resistance in S.
aureus [112]. Interestingly, this compound was found to inhibit also
LPS-mediated activation of macrophages at nM concentrations [113].
The pore forming properties of these oligomers have been investi-
gated using various biophysical techniques including, Langmuir ﬁlms
at the air–water interface [114,115], grazing incidence X-ray diffraction
[116], small angle X-ray scattering [117], sum frequency generation
vibrational spectroscopy [118], and dye leakage experiments from
model membranes [117]. Thus, when the ethylamine group of
compound 1 was shortened to a single methylene, activity against
both bacteria and RBCs was lost. In contrast, when the ethylamine
group was extended to propylamine it showed activity against both
bacteria and RBCs. Furthermore, compound 1 induced maximal dye
leakage from vesicles reconstituted from E. coli lipid extract. Unlike its
propylamine analog, leakage was reduced when supplemented with
phosphotidylcholine, suggesting that compound1, inducedmembrane
damage by a mode of action that resembles many AMPs, whose
selectivity is dependent on anionic lipids concentration.
Collectively, such AMPmimics were shown to overcome one of the
main shortcomings of α peptides – susceptibility to enzymatic
degradation – suggesting improved antibacterial properties in vivo.
However, to the best of our knowledge, there are no such studies
published as yet, for any of the above mentioned peptide-mimics.
3. Introduction to OAQs: SAR studies of dermaseptins
The AMPs mode of action has been traditionally investigated using
sequence speciﬁc modiﬁcations or de-novo design of AMP analogs.
Many of these studies were based on the assumption that the
secondary structure played a key role and consequently attempted to
improve antimicrobial properties via improving structural aspects. We
among others, have long been studying structural effects on
antimicrobial properties using the frog dermaseptin family as model
AMPs [51,119–122]. However, we eventually realized that while
enhancing the helical content did in fact enhance antimicrobial
potency, it also reduced the peptide's ability to discriminate between
target cells. For instance, sequence manipulations of dermaseptin S4
led to the analog K4K20-S4, a highly structured peptide with potent
and large spectrum antimicrobial activity [120,123]. This analog
however, was among the most hemolytic peptides ever described in
the literature, with obvious in-vivo toxicity [124]. We suspected
therefore, that this strategy had a dead end that severely limited the
potential use of AMPs, especially towards systemic applications.
We therefore turned to newalternatives, seeking at ﬁrst to improve
selectivity via short (truncated) analogs of natural dermaseptins. This
strategy also turned out to be disappointing although not devoid of
some interest. Thus, elimination ofﬂexible peptide domains indeed led
to short α-helical derivatives with reduced hydrophobicity but with
improved selectivity [120,125]. N-terminus acylations – which
represented a convenient means, from the synthetic point of view, to
compensate/modulate for hydrophobicity loss – revealed to
signiﬁcantly affect the peptide amphipathic organization and
activities. Thus, acylated short derivatives that maintained α-helical
conformation displayed improved selectivity [51,119]. Interestingly,
Fig 2. Dermaseptin to OAK evolution. (a) Full length native dermaseptin S4(1–28) [141]; (b) Truncated derivative K4-S4(1–13) [125]; (c) Lipopeptide version of the truncated
derivative, animoheptanoyl-lysyl-S4(5–13) [126]; (d) OAK version, animoheptanoyl-lysyl-2α8 [130].
Fig. 3.HQmap of 105 OAKs. Shown are the HQ values of each OAK (numbered from 1 to
105). Most sequences (103) are listed in [127]. New OAKs are: C16K-1β12 (number 104,
H=56, Q=3) and C10K-3β12 (number 105, H=44, Q=7). Highlighted (red circles)
are potent OAKs (displaying MIC≤3 μM). These were found to concentrate in a narrow
band of HQ values (highlighted in blue).
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substitute for considerably lengthyN-terminal sequences,maintaining
some helical conformation but displaying a highly narrow spectrum of
activity, which included practically only pseudomonal species [126].
These attempts nonetheless, raised the possibility that acyl moieties
might be able to substitute extensive sequences within the peptide
backbone (i.e., the OAQ concept), suggesting that the consequence of
losing the secondary structure might be rather advantageous,
especially in terms of selectivity (as detailed below). The structural
evolution from a native dermaseptin to an OAK is illustrated in Fig. 2.
3.1. OAQs design
To investigate the link between antimicrobial- and folding-
properties of AMPs, we recently designed a library of peptide-like
sequences where lack of a deﬁned secondary structure was promoted
by an acyl chain bridging between two cationic amino acids, according
to the general formula: [AiQ]n where A and Q represent an acyl (a
fatty- or amino fatty-acid of variable length (i)) and a charged amino
acid, respectively. The following descriptions will refer to oligomers of
acylated lysine (AK), i.e., a particular case ofOAQswhereQ= lysine (K).
The aminoacyl-lysyl building block is termed αi subunit while lysyl-
aminoacyl-lysyl is termed βi subunit, where i deﬁnes the number of
carbon atoms in the acyl chain (for example, α4 is an aminobutyryl-
lysine subunit). While providing both hydrophobicity and positive
charge features, these molecules are expected to limit formation of
deﬁned secondary structures because of the optimal rotational freedom
of the carbon atoms in an acyl chains (the particular case of long acyls
will be discussed below). This method therefore enables a structure-
independent and systematic tool for a gradual control of molecular
hydrophobicity (by changing acyl chain length). Similarly, using this
approach, comparisons between α- and β-OAKs can reveal the
importance of charge distribution (by changing the nature, the position
and/or the number of cationic residues). An OAK library including over
one hundred sequences was produced and characterized [127]. As
detailed in the following paragraphs, analysis of the obtained data
enabled to draw pertinent conclusions as to the physico-chemical
properties required for potency and selectivity of OAKs.3.2. Relationships between HQ values and antibacterial properties
The OAKs physical and antibacterial properties (assessed against
E. coli) are summarized in Fig. 3 which also highlights the fact that
they cover awide range of hydrophobicity (H=up to 60%) and charge
(Q=up to +11) values. Three major trends have emerged:
1) The OAK biophysical properties are dictated by the nature of the N-
terminal acyl [127]. For instance, in OAKs that lack an N-terminal
acyl, theH value readily increasedwith increasing backbone length,
Table 1
Biophysical properties of typical short OAKs
OAKa Qb Hc (%) CACd (μM) MICe (μM) LC50f (μM), RBC
E. coli S. aureus
C12K-2α12 3 52.9 b1 N50 N50 8±1
C12K-2β12 5 51.0 11.2±2.5 3.1 6.3 88±3
C12K-1β12 3 54.0 9.6±1.6 25 3.1 29±9
C12(ω7)K-1β12 3 50 50 N50 3.1 100±8
a Designation,C12K=lauryl-lysyl;α12=aminolauryl-lysyl;β12=lysyl-aminolauryl-lysyl.
b Molecular charge at physiological conditions.
c Hydrophobicity, deﬁned the percent acetonitrile eluent on a C18 HPLC column.
d Critical aggregation concentration evaluated by linear extrapolation of light
scattering.
e Lowest OAK concentration that fully inhibited bacterial growth (N99%) after 24 h
culture at 37 °C.
f OAK concentration that induced 50% hemolysis (1% hematocrit) after 3 h incubation;
values represent themean±standard deviationof at least two independent experiments.
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which remained practically constant regardless of the number and
type of subunits. This hydrophobicity stabilization often allows
focusing on effects speciﬁc to charge upon subunit variations.
2) Antibacterial activity emerged when the OAK attained an optimal
window of HQ values [127]. Potent antibacterial activity
(MIC≤3 μM) required a relatively narrow window of HQ values
and disregarded the speciﬁc OAK sequence (Fig. 3). For E. coli,
these values were: H=50±2 and Q=6.5±2 (mean and SD
calculated from the H and Q values of the most active OAKs). Note
however that different HQ windows were obtained for different
bacteria and although these might be grouped in terms of gram-
negative and gram-positive bacteria, an overlapping zone seems to
emerge that includes essentially non-speciﬁc antibacterial OAKs.Fig. 4. Relationships between hemolysis and organization in solution. Panel A shows the hem
subunits but varying in length of intercalating acyls) determined against Human RBC (1% he
7α12, red; C12K-7α8, green; C12K-7α4, blue. Panel B compares the circular dichroism spectra o
α12-OAK at 1 mg/ml (Bar=50 nm) showing its self-assembly in aqueous solution [128]. Pa
shows two OAK sequences based on C8 and C12 acyls (left and right, respectively). In aqueou
subsequently associate to form micron-long multimers (panel C). Such structures would
enough) by hydrogen bonds between backbone amides within each molecule and in adjaceThis suggested the possibility that the OAK systemmight be able to
uncover speciﬁc compounds per groups of bacteria.
3) Self-assembly properties can often explain discrepancies such as
why the “active HQ window” contains seemingly inactive OAKs.
Presumably, large supramolecular structures are prohibited from
reaching internal targets that might be located beyond the
bacterial cell wall. By using EDTA (which increases external
membrane permeability) we showed that aggregated OAKs within
the HQ window are potentially active but due to their aggregated
state, are excluded by the bacterial cell wall [127]. Thus, this assay
allows the distinction between “truly” inactive OAKs (i.e., those
that lack the HQ properties required for activity) and potentially
active OAKs. This is not to say that all types of aggregates are
necessarily inactive, especially considering that an aggregated
compound can be inactive against a given microorganism but
active against another. An interesting example is represented by
recent ﬁndings showing that short OAKs displayed potent
antibacterial properties at concentrations above the CAC value
([128] and Table 1). Another example is represented by previous
ﬁndings showing that various additional aggregated OAKs that
were inactive against bacteria displayed potent antiplasmodial
properties [129], supporting the notion that interactions of
aggregates with eukaryotic (as opposed to prokaryotic) cells are
governed by different rules, if only due to lack of a cell wall.
3.3. Relationships between 3D structure and hemolytic activity
As exempliﬁed in Fig. 4, butyl- and octyl-based OAKs were
consistently devoid of hemolytic activity at least up to 150 μM (a
concentration that represents ∼100-folds the MIC value) whereas
their circular dichroism (CD) proﬁles in PBS were characteristic ofolytic activity of three representative OAKs (with identical N-terminus and number of
matocrit, 3 hour incubation at 37 °C in PBS). Error bars represent±1 SD. Colors: C12K-
f the same OAKs (100 μM) in PBS. Panel C, shows a cryo-TEM image of a representative
nel D depicts a hypothetical model for organization of representative OAKs. Upper line
s solution, only long enough acyl residues can fold into amphipathic structures that can
be stabilized primarily by hydrophobic interactions and eventually (if packed tightly
nt layers.
Fig. 5. Assessment of the mode of action. (A) Cytoplasmic membrane depolarization of
E. coli. Test compounds were added to cell suspensions at 6xMIC and changes in
ﬂuorescence were recorded online. Symbols (same for panels A–D): C12K-5α8, circles;
C12K-7α8, squares; dermaseptin S4(1–16), triangles; bacterial suspension without
treatment, upside triangles. Note: Panels A and C depict continuous recordings, symbols
were added for clarity. (B) Viability of EDTA-treated bacteria. Aliquots from bacterial
suspensions described in A, were plated for CFU count after overnight incubation. (C)
Kinetics of ONPG hydrolysis in E. coli ML35 measured by incubating bacteria with test
compounds at 6xMIC. (D) Leakage of E. coli ML35 intracellular β-galactosidase to the
surrounding medium following exposure to the test compounds at 6xMIC, assessed by
monitoring enzymatic activity upon mixing ONPG with the suspension's supernatant.
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and other hydrophobic media [130]. Thus, unlike most AMPs,
antibacterial activity of these AMP-mimetic OAKs can be highly
dissociated from both stable conformation and hemolytic activity.
Lauryl-based OAKs however, were often hemolytic, highly aggregated
anddisplayedCDproﬁles of stable folds reminiscent to those ofα-helix
or β-sheet structures [131]. The fact that non-random CD proﬁles were
observed only with aggregated OAKs suggests that these CD proﬁles
rather reﬂect supra-molecular organizations. In fact, as exempliﬁed in
Table 1, attempts to limit aggregation either by increasing backbone
charge (e.g., using β-subunits [127] or through the use of unsaturated
acyls [128] lead, in both cases, to simultaneous loss of hemolytic
activity and “normalization” of the CD proﬁle.
The correlation existing between aggregated OAKs and hemolytic
activity provides a strong support to the hypothesis underlying OAKs
design [130], proposing a link between stable folds (i.e., rigid
structures) and hemolytic properties of AMPs. According to this
hypothesis, rigid structures (if hydrophobic enough) can interact with
RBC membrane in a manner that perturbs its architecture and lead to
hemoglobin leakage, whereas, due to their high backbone malleability
(i.e., non-rigid structures) OAKs interactions with RBC membrane
would be inefﬁcient in perturbing the membrane. Indeed, the data
indicate that incorporation of fatty acids within a peptide backbone
can suppress the formation of a stable molecular fold — if the
intercalating acyl chains are not too long (i.e., must be shorter than
twelve carbons). Conceivably, unlike shorter acyls, lauryl residues are
long enough to bend and create rigid amphipathic structures, hence
their propensity to stabilize in aqueous solutions through self-
assembly (aggregates) and their hemolytic activity, reﬂecting their
ability to reorganize within membranes in presence of RBC. Fig. 4
depicts a drawing of such potential aggregates that can interact with
RBC membrane and perturb its architecture, much like amphipathic
conventional AMPs [51,125,132].3.4. OAKs can affect bacterial viability by a variety of distinct mechanisms
The ﬁrst OAK investigated was found to exert antibacterial activity
through membrane disruption [130]. Further investigations however,
revealed that the OAK library contains additional antibacterial OAKs,
sometimes very closely related, that acted by different mechanisms of
action. For instance, various analogous OAKs revealed drastically
different time-kill curves, e.g., minutes versus hours [133]. The
differential killing rates of these OAKs was proposed to reﬂect
different targets such as cytoplasmic membrane disruption and
interference with intracellular processes. This view was supported
by several studies of a pair of analogous OAKs, the octamer C12K-7α8
and the hexamer C12K-5α8 [133,134]. On one hand, the OAKs displayed
similar properties in many respects, suggesting a similar mode of
action: Both OAKs exerted a bactericidal effect, displayed high binding
afﬁnities to model membranes, similar stability in blood while
bacteria were unable to develop resistance to either OAK [133].
Moreover, in-vivo studies also showed similar pharmacokinetics and
similar abilities to protect mice from a lethal bacterial infection [133].
However, additional probing experiments revealed a different
picture, rather arguing for distinct mechanisms. Thus, differential
time-kill rates of the analogous OAKs correlated with rates of
depolarization of the bacterial membrane potential and with rates of
leakage of an intracellular enzyme (Fig. 5). These results indicated that
only C12K-7α8 induced bacterial death through disruption of the
cytoplasmic membrane (Fig. 6). In contrast, only C12K-5α8 displayed
the ability to translocate across the cytoplasmicmembrane and interact
with nucleic acids [133]. The incapacity of C12K-7α8 for a similar
behavior is probably (at least partly) linked to it stronger interaction
with cell wall components (e.g., LPS) as well as with cytoplasmic
membrane phospholipids. Once C12K-7α8 reaches the cytoplasmic
membrane anddisrupts it, themembrane potential is canceled and so is
the driving force for translocation. Conversely, C12K-5α8 reduced
positive charge is likely to comparatively reduce all interactions on
the way to the cytoplasmic membrane where the trans-membrane
potential difference can be used as the driving force for internalization,
thereby promoting its interaction with intracellular targets.
A recent study using ITC to compare the analogs interaction with
model phospholipid membranes, conﬁrmed the higher binding
afﬁnity of C12K-7α8 (as observed using SPR [133]) and further DSC
and NMR studies indicated that only C12K-7α8 had the ability to
induce the clustering of anionic lipids [134]. This clustering effect is
believed to lead to the lateral segregation of domains rich in anionic or
zwitterionic lipids, producing phase boundary defects that ultimately
breach the permeability barrier of the cell membrane.
The ﬁnding that OAK analogs can use distinct mechanisms of
action is therefore surprising although not unprecedented. While
most conventional AMPs are believed to act by destabilizing the
plasma membrane, there is a growing list of peptides such as PR-39
[60], buforinII [135], pyrrhocoricin [59], tPMP-1 and HNP-1 [136], all
proposed to induce bacterial death through interaction with intra-
cellular targets. Combined with the OAK data, these ﬁndings show
that tiny differences (such as a single charge and/or backbone length)
are required for an antibacterial compound to switch from one
mechanism to another. Stretching this idea further, the data also raise
the possibility that the simultaneous production of multiple closely
related host defense peptides might be linked to an evolutionary
advantage providing the producing cell/tissue with a highly efﬁcient
attack system that uses both synergistic strategies as previously
proposed [137,138] and multiple mechanisms to combat a larger
spectrum of pathogens.
3.5. Antiplasmodial properties of OAKs
Targeting of intracellular parasites provides a challenging model
system for development of selectivity in “non-speciﬁc” antimicrobial
Fig. 6. Schematic diagram of OAKs antibacterial modes of action. Upper diagram depicts an OAKmolecule composed of three acyls (yellow) and lysines (blue) about to interact with a
model membrane composed of lipids with two different kinds of headgroups, represented by red and cyan balls. The lower diagrams depict three potential modes of action
representing (from right to left) a drastic perturbation of the membrane structure (equivalent to punching holes in the membrane) which involve leakage of intracellular
components, as observedwith C12K-7α8 [130]; themiddle diagram represents amilder damage to themembrane, as observedwith C12K-7α8 [134], where the preferential interaction
of the OAK with one of the lipids leads to phase separation of lipids. This creates phase boundary defects between domains enriched in either of the two lipids; The left diagram
represents the trans-localization (internalization) of the OAK to the cytoplasmic compartment (without causing any noticeable membrane damage), followed by inhibition of DNA
functions through (probably non-speciﬁc) high afﬁnity binding to DNA, as observed for C12K-5α8 [133].
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dermaseptins in cultures of Plasmodium falciparum, have shown that
native dermaseptins kill intraerythrocytic malaria parasites through
lysis of the host cells [123]. Acylation of the truncated derivative S4
(1–13) resulted in an ampliﬁed antiplasmodial effect [139]. Although
increased hydrophobicity was generally associated with increased
hemolysis, various derivatives, such as isobutyryl [139] and amino-
heptanoyl [140] analogs displayed improved selectivity (i.e., were
more effective antiplasmodials yet less hemolytic). These studies
suggested that AMPs could be engineered to speciﬁcally target the
intra-erythrocyte parasite and prompted the investigation of the
antiplasmodial properties of OAKs.
Certain lauryl based OAKs were found to display a highly selective
antiparasitic activity [129] where the ratio of LC50 (hemolysis) to IC50
(parasite growth inhibition) was N10,000 for the most selective OAK,
composed of three α12 subunits (3α12). In achieving this selectivity,
we have circumvented the major handicap of dermaseptins and their
derivatives observed before, i.e., their hemolytic activity [123,139,140].
The most active OAK, lauryl-lysyl-3α12, displayed an IC50 of 0.08 μM
and a selectivity ratio of N1,000. Although it was not possible to
discriminate between the lysis of infected cells and the lysis of the
uninfected cohort, the overall lysis was very small at the relevant
antiplasmodial concentrations. These results indicated that the OAKs
did not exert their antimalarial action by lysis of infected RBC, as was
the cases with the parent dermaseptins [123] and pointed to the
potential of the OAQ system to generate highly selective low-cost
compounds that might be useful in ﬁghting Malaria.
4. Conclusions
When examining nearly a thousand sequences of natural AMPs
(http://www.bbcm.univ.trieste.it/~tossi), one can ﬁnd neither a
meaningful consensus sequence nor even a common secondary
structure. The only common feature is the occurrence of bothhydrophobic and positively charged amino acids, suggesting that in
principle, the requirements for antimicrobial activity do not include a
deﬁned secondary structure.Moreover,while SAR studies of AMPshave
pointed to probable sites of action they failed in providing an optimal
resolution as to the individual importance ofmolecular hydrophobicity
and positive charge. Such an opportunity was considerably approached
via peptidomimetics. Namely, the inherently simple and incremental
nature of the OAQ libraries, provide a systematic tool for the dissection
of the relative importance of charge and hydrophobicity and pin down
their respective role(s). In this respect, since the available data support
the concept that a deﬁned secondary structure does not necessarily
play a determining role, activity can be made to depend solely on a
subtle interplay between positive charge and hydrophobicity. One
might anticipate therefore, that AMP-mimetics can be useful in better
understanding the role and function of host defense peptides andmight
also considerably increases the potential of uncovering low-cost highly
selective derivatives that will be beneﬁcially utilized in various
antimicrobial ﬁelds, including in systemic treatment of medical
conditions associated with MDR pathogens.References
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